Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Wants FDA Plan To Speed Obesity Drug Development

This article was originally published in The Pink Sheet Daily

Executive Summary

Appropriations Committee considers obesity a "significant unmet medical need."
Advertisement

Related Content

Vivus Qsymia Launch Includes Strategy To Overcome Medicare Hurdles
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA’s Funding Outlook Is Relatively Sunny, But Best For Growing Food
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

Topics

Advertisement
UsernamePublicRestriction

Register

PS072860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel